Takeda Pharmaceutical Company Limited

TSE:4502 Stock Report

Market Cap: JP¥6.5t

Takeda Pharmaceutical Past Earnings Performance

Past criteria checks 1/6

Takeda Pharmaceutical has been growing earnings at an average annual rate of 16.6%, while the Pharmaceuticals industry saw earnings growing at 5.6% annually. Revenues have been growing at an average rate of 9.8% per year. Takeda Pharmaceutical's return on equity is 2%, and it has net margins of 3.4%.

Key information

16.6%

Earnings growth rate

13.5%

EPS growth rate

Pharmaceuticals Industry Growth3.4%
Revenue growth rate9.8%
Return on equity2.0%
Net Margin3.4%
Next Earnings Update31 Jul 2024

Recent past performance updates

Some Investors May Be Willing To Look Past Takeda Pharmaceutical's (TSE:4502) Soft Earnings

May 21
Some Investors May Be Willing To Look Past Takeda Pharmaceutical's (TSE:4502) Soft Earnings

Recent updates

Takeda Pharmaceutical (TSE:4502) Takes On Some Risk With Its Use Of Debt

Jun 11
Takeda Pharmaceutical (TSE:4502) Takes On Some Risk With Its Use Of Debt

Some Investors May Be Willing To Look Past Takeda Pharmaceutical's (TSE:4502) Soft Earnings

May 21
Some Investors May Be Willing To Look Past Takeda Pharmaceutical's (TSE:4502) Soft Earnings

Takeda Pharmaceutical Company Limited Just Recorded A 6.0% EPS Beat: Here's What Analysts Are Forecasting Next

May 12
Takeda Pharmaceutical Company Limited Just Recorded A 6.0% EPS Beat: Here's What Analysts Are Forecasting Next

Takeda Pharmaceutical (TSE:4502) Is Due To Pay A Dividend Of ¥94.00

Mar 28
Takeda Pharmaceutical (TSE:4502) Is Due To Pay A Dividend Of ¥94.00

Takeda Pharmaceutical (TSE:4502) Has Announced A Dividend Of ¥94.00

Mar 13
Takeda Pharmaceutical (TSE:4502) Has Announced A Dividend Of ¥94.00

Takeda Pharmaceutical (TSE:4502) Will Pay A Dividend Of ¥94.00

Feb 26
Takeda Pharmaceutical (TSE:4502) Will Pay A Dividend Of ¥94.00

Revenue & Expenses Breakdown

How Takeda Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TSE:4502 Revenue, expenses and earnings (JPY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 244,263,762144,0671,053,819729,924
31 Dec 234,169,049178,2191,023,306695,012
30 Sep 234,154,414191,6261,018,085682,260
30 Jun 234,113,631301,3981,013,867652,459
31 Mar 234,027,478317,017997,234633,325
31 Dec 223,944,611274,525965,908616,009
30 Sep 223,749,354213,167934,687569,758
30 Jun 223,591,868197,389897,964547,214
31 Mar 223,569,006230,059886,327526,087
31 Dec 213,465,991438,515897,171495,680
30 Sep 213,401,450473,105888,737484,868
30 Jun 213,345,565431,178892,983471,424
31 Mar 213,197,812376,005875,514455,765
31 Dec 203,199,240180,631895,464486,660
30 Sep 203,221,80456,051921,830491,903
30 Jun 203,243,917119,743928,229486,343
31 Mar 203,291,18844,241964,268492,088
31 Dec 193,236,69713,275965,530485,736
30 Sep 192,876,78283,262867,314440,388
30 Jun 192,496,51163,959790,113407,257
31 Mar 192,097,224135,192692,728368,257
31 Dec 181,780,976110,414608,443317,675
30 Sep 181,769,726140,738616,726321,777
30 Jun 181,772,125120,339622,667321,719
31 Mar 181,770,531186,886628,106325,441
31 Dec 171,785,773190,172632,833324,485
30 Sep 171,762,667163,457622,191314,755
30 Jun 171,746,286160,202616,779310,763
31 Mar 171,732,051114,940615,867311,625
31 Dec 161,729,967132,194614,187312,149
30 Sep 161,754,130150,081627,784332,841
30 Jun 161,795,088155,110633,600337,807
31 Mar 161,807,37880,166650,336335,704
31 Dec 151,831,096-111,874650,103386,767
30 Sep 151,830,521-152,827642,957386,950
30 Jun 151,812,971-154,591637,726387,932
31 Mar 151,777,824-145,775612,489367,741
31 Dec 141,744,79575,405474,242356,593
30 Sep 141,714,694103,390497,474342,907
30 Jun 141,692,531110,981522,831339,169
31 Mar 141,691,685106,658556,210341,560
31 Dec 131,655,033103,3301,036,83110,620
30 Sep 131,598,67476,159575,620324,787
30 Jun 131,569,27772,757557,783322,960

Quality Earnings: 4502 has a large one-off loss of ¥150.0B impacting its last 12 months of financial results to 31st March, 2024.

Growing Profit Margin: 4502's current net profit margins (3.4%) are lower than last year (7.9%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 4502's earnings have grown by 16.6% per year over the past 5 years.

Accelerating Growth: 4502's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 4502 had negative earnings growth (-54.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (13.3%).


Return on Equity

High ROE: 4502's Return on Equity (2%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.